ZAI LAB LTD0000006 (1ZLB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ZAI LAB LTD0000006 (1ZLB) has a cash flow conversion efficiency ratio of -0.036x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-26.02 Million ≈ $-30.42 Million USD) by net assets (€715.50 Million ≈ $836.49 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
ZAI LAB LTD0000006 - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how ZAI LAB LTD0000006's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read ZAI LAB LTD0000006 (1ZLB) financial obligations for a breakdown of total debt and financial obligations.
ZAI LAB LTD0000006 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ZAI LAB LTD0000006 ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Suzhou TZTEK Technology Co Ltd
SHG:688003
|
0.001x |
|
Electra Ltd
TA:ELTR
|
0.046x |
|
HENSOLDT AG UNSP. ADS
F:HAG0
|
N/A |
|
Rendong Holdings Co Ltd
SHE:002647
|
0.089x |
|
Central China Securities Co Ltd
SHG:601375
|
0.335x |
|
Perdoceo Education Corp
NASDAQ:PRDO
|
0.041x |
|
Penn National Gaming Inc
NASDAQ:PENN
|
0.059x |
|
Oesterr. Post AG
VI:POST
|
0.083x |
Annual Cash Flow Conversion Efficiency for ZAI LAB LTD0000006 (2021–2025)
The table below shows the annual cash flow conversion efficiency of ZAI LAB LTD0000006 from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see ZAI LAB LTD0000006 (1ZLB) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €715.50 Million ≈ $836.49 Million |
€-150.79 Million ≈ $-176.29 Million |
-0.211x | +17.52% |
| 2024-12-31 | €840.90 Million ≈ $983.10 Million |
€-214.87 Million ≈ $-251.20 Million |
-0.256x | -2.65% |
| 2023-12-31 | €796.12 Million ≈ $930.75 Million |
€-198.18 Million ≈ $-231.69 Million |
-0.249x | +29.20% |
| 2022-12-31 | €1.05 Billion ≈ $1.22 Billion |
€-367.64 Million ≈ $-429.81 Million |
-0.352x | +11.66% |
| 2021-12-31 | €1.38 Billion ≈ $1.61 Billion |
€-549.23 Million ≈ $-642.11 Million |
-0.398x | -- |
About ZAI LAB LTD0000006
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for … Read more